Hoth Therapeutics IncHoth Therapeutics Inc
RKTOHealth Care·Biotechnology
Rocket One, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in Hoboken, NJ.
New York; U.S.A
Market cap
$16.2MNo data
Revenue
No dataNo data
Net income
No dataNo data
Free cash flow
No dataNo data
Cash and equivalents nearly match equity and dwarf liabilities, with a current ratio above 6 indicating substantial unused liquidity. Revenue, profit, and earnings-quality metrics for the quarter are unavailable.
As of 2026-06-30Market
Listed stock
RKTOPriceNasdaqLoading…Loading…1Y